Introduction:

In the fall of 2000, a young healthy male died following snorting an excessive amount of 2C-T-7.  Since this initial 2C-T-7-related death, two additional deaths reported in April 2001 have been linked to 2C-T-7.  These two deaths resulted from the co-abuse of 2C-T-7 with MDMA.

Licit Uses:

2C-T-7 is not approved for marketing by the Food and Drug Administration and is not sold legally in the United States.

Chemistry and Pharmacology:

2,5-Dimethoxy-4- (n)-propylthiophenethylamine (2C-T-7), is a phenethylamine hallucinogen that is structurally related to the schedule I phenethylamine hallucinogens, 4-bromo-2, 5-dimethoxyphenethylamine (2C-B, Nexus) and mescaline.  Based on structural similarly to these compounds, the pharmacological profile of 2C-T-7 is expected to be qualitatively similar to these hallucinogens.

Drug discrimination studies in animals indicate that 2C-T-7 produces discriminative stimulus effects similar to those of several schedule I hallucinogens.  In rats trained to discriminate 2,5-dimethoxy-4-methyl-amphetamine (DOM), 2C-T-7 fully substituted for DOM and was slightly less potent than 2C-B in eliciting DOM-like effects.  2C-T-7 was also shown to share some commonality with LSD; it partially substituted for LSD up to doses that severely disrupted performance in rats trained to discriminate LSD.  2C-T-7 can also function as a discriminative stimulus in rats.  Rats readily learned to discriminate 2C-T-7 from saline.  When either 2C-B or LSD was substituted for 2C-T-7, each elicited 2C-T-7-like discriminative stimulus effects. The subjective effects of 2C-T-7, like those of 2C-B and DOM, appear to be mediated through central serotonin receptors.  2C-T-7 selectively binds to the 5-HT receptor system.

According to one published case report, 2C-T-7 abuse has been associated with convulsions in humans.

Illicit Uses:
2C-T-7 is abused orally and intranasally for its hallucinogenic effects. Information from a website about a variety of illicit drugs has suggested that 2C-T-7 produce effects similar to those of 2C-B.  This information is based on individuals self-administering 2C-T-7 illicitly and self-reporting the effects.  Its effects include visual hallucination, mood lifting, sense of well being, emotionality, volatility, increased appreciation of music, and psychedelic ideation.  The oral and intranasal doses recommended on this website are 10-50 mg and 5-10 mg, respectively.  2C-T-7’s onset and duration of actions are dependent upon the route of administration.  Following oral administration, onset and duration of effects are 1 to 2.5 hours and 5 to 7 hours, respectively.  After intranasal administration, the onset of action and duration of effects are 5 to 15 minutes and 2 to 4 hours, respectively.

User Population: 

Young adults are the main abusers of 2C-T-7.

Illicit Distribution:

According to National Forensic Laboratory Information System (NFLIS), law enforcement  officials seized and submitted 38 items (9 cases) of 2C-T-7 to state and local forensic laboratories from 2004 to 2008.  Seizures of 2C-T-7 have occurred in California, Florida, Minnesota and Wisconsin in the last five years.  A vast majority of the drugs (29 items from 2 cases) were seized in the state of Florida.  There were no 2C-T-7 drug items submitted and analyzed by DEA laboratories from 2004 to 2008.

2C-T-7 was being purchased over the Internet from a company located in Indiana.  This site was traced to an individual who had been selling large quantities of this substance since January 2000.  Sales through this Internet site were thought to be the major sources of 2C-T-7 in the United States.  One clandestine laboratory was identified in Las Vegas, Nevada as the supplier of 2C-T-7 to the individual in Indiana. 2C-T-7 has been sold under the street names Blue Mystic, T7, Beautiful, Tweety-Bird Mescaline or Tripstay.

Control Status:

2C-T-7 has been placed in Schedule I of the Controlled Substances Act of 1970.

Comments and additional information are welcomed by the Drug and Chemical Evaluation Section.  Fax 202-353-1263, telephone 202-307-7183, or Email ODE@usdoj.gov.